CytoArm’s Global Patent Portfolio
At CytoArm, we are pioneering innovative cancer treatment solutions through our Armed-T platform. Our expansive and growing patent portfolio demonstrates the strength and uniqueness of our cutting-edge technology. Below are key milestones showcasing our global patent filings, approvals, and successes.
Patent Filing and Approval Milestones
2017
- Mar 2017
CytoArm filed a US provisional patent application for its revolutionary Armed-T technology.
2018
- Mar 2018
CytoArm filed a Patent Cooperation Treaty (PCT) Application with the World Intellectual Property Organization (WIPO) to protect its T-cell therapy innovations globally.
- Mar 2018
Patent application submitted to the Taiwan Intellectual Property Office (R.O.C). Total: 1 PCT, 2 Patent applications.
2019
- Sep 2019
Patent filed with the Australian IP Office, marking further global expansion of CytoArm’s patent strategy. Total: 1 PCT, 3 Patent applications.
- Sep 2019
Patents filed with the European Patent Office and China National Intellectual Property Administration. Total: 1 PCT, 4 Patent applications.
- Sep 2019
Patent filed with the Japan Patent Office. Total: 1 PCT, 5 Patent applications.
- Sep 2019
Patent filed with the United States Patent and Trademark Office. Total: 1 PCT, 6 Patent applications.
- Oct 2019
Patent filed with the Korean Intellectual Property Office. Total: 1 PCT, 7 Patent applications.
- Nov 2019
First granted patent from the Taiwan Intellectual Property Office. Total: 1 PCT, 6 Patent applications, 1 Patent Granted.
2020
Nov 2020
Divisional patent granted by Taiwan Intellectual Property Office. Total: 1 PCT, 6 Patent applications, 2 Patents Granted.
Mar 2020
CytoArm filed a new US provisional patent application.
2021
- Mar 2021
CytoArm filed a second PCT Application with WIPO, further expanding its international patent coverage.
- Mar 2021
Patents filed with the Taiwan Intellectual Property Office and Japan Patent Office. Total: 2 PCT, 7 Patent applications, 2 Patents Granted.
2022
- Feb 2022
Patent granted by the Korean Intellectual Property Office. Total: 2 PCT, 6 Patent applications, 3 Patents Granted.
- Feb 2022
Divisional patent filed with the Australian IP Government. Total: 2 PCT, 7 Patent applications, 3 Patents Granted.
- Mar 2022
Patent granted by the Japan Patent Office. Total: 2 PCT, 6 Patent applications, 4 Patents Granted.
- May 2022
Patent granted by the Australian IP Government. Total: 2 PCT, 5 Patent applications, 5 Patents Granted.
- Aug 2022
CytoArm filed its third PCT Application, further enhancing global intellectual property protection.
2023
- Dec 2023
Continuation In-Part Patent filed with the United States Patent and Trademark Office.
2024
- Feb 2024
Patent granted by the United States Patent and Trademark Office, further strengthening CytoArm’s intellectual property in the U.S.
- Mar 2024
Patent filed with the European Patent Office. Total: 3 PCT, 15 Patent applications, 6 Patents Granted.
Ongoing and Future Patents
CytoArm continues to expand its global patent portfolio, ensuring comprehensive protection of our Armed-T platform and innovative therapies. Stay tuned for updates on our latest patent filings and newly granted patents, as we continue to push the boundaries of cancer immunotherapy.
Reference: 2024 PCT 157 Contracting States, https://www.wipo.int/pct/en/pct_contracting_states.html
English 
Chinese